Unlabelled: We retrospectively investigated patients with small-cell lung cancer with or without interstitial lung disease (ILD). Response rates and median progression-free survival of first-line chemotherapy in patients with or without preexisting ILD was not significantly different. However, pneumonitis associated with chemotherapy was significantly increased in patients with preexisting ILD, and preexisting ILD is an independent prognostic factor for poorer survival.

Background: In Japan, iatrogenic acute exacerbation of interstitial lung disease (ILD) is a serious complication in patients with lung cancer and simultaneous ILD. Results of some reports suggest that patients with ILD and small-cell lung cancer (SCLC) might benefit from chemotherapy, but the influence of ILD on prognosis is unclear.

Patients And Methods: Retrospective study of patients with SCLC with or without ILD. Between April 2006 and March 2011, 122 patients with SCLC who were receiving platinum-based combination chemotherapy participated.

Results: Twenty-eight patients (23.0%) had ILD at diagnosis. Pneumonitis associated with chemotherapy, including acute exacerbation-ILD was significantly increased in patients with preexisting ILD (8/28 vs. 2/94; P = .0001). In patients receiving chemotherapy alone, response rates and median progression-free survival of first-line chemotherapy in patients with or without preexisting ILD was not significantly different (P = .26; 20/26 vs. 52/60 and P = .089; 4.4 months vs. 5.4 months, respectively). The median overall survival of all patients was 15.5 months, but those without preexisting ILD survived significantly longer (P = .0010; 17.8 months vs. 10.7 months). Multivariate analysis revealed that performance status of 0 or 1 (hazard ratio [HR] 0.19 [95% confidence interval {CI}, 0.10-0.37]; P < .0001) limited disease (HR 0.42 [95% CI, 0.23-0.73]; P = .0017), and no preexisting ILD (HR 0.36 [95% CI, 0.19-0.69]; P = .0027) were significantly associated with longer overall survival.

Conclusion: Patients with SCLC and ILD might benefit from chemotherapy, but preexisting ILD is an independent prognostic factor for poorer survival.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2011.11.001DOI Listing

Publication Analysis

Top Keywords

preexisting ild
32
lung cancer
16
ild
16
patients preexisting
16
patients
14
interstitial lung
12
lung disease
12
small-cell lung
12
patients sclc
12
preexisting
9

Similar Publications

Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy.

J Dermatolog Treat

December 2024

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Article Synopsis
  • * A case study of a 69-year-old man highlighted respiratory issues after 18 months of treatment, revealing significant lung damage through medical imaging and biopsy, which pointed to immune cell involvement.
  • * The findings emphasize the need for close lung monitoring in patients on biologic therapies, especially those with existing lung problems, as ixekizumab may lead to serious inflammatory responses.
View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to investigate the safety and effectiveness of docetaxel/ramucirumab (DOC/RAM) therapy in patients with advanced non-small cell lung cancer (NSCLC) who also had interstitial lung disease (ILD).
  • The study found that 25% of patients with pre-existing ILD developed DOC/RAM-induced interstitial pneumonia, while no patients without ILD experienced this condition.
  • Despite the increased incidence of pneumonia in those with ILD, the treatment did not significantly impact the overall treatment outcomes like objective response rate, progression-free survival, or overall survival.
View Article and Find Full Text PDF

Background: Drugs used to treat rheumatic disease are associated with pneumotoxicity (drug-induced lung disease), but little is known about associated risk factors.

Aim: To determine expert physician-perceived risk factors for developing pneumotoxicity in patients with rheumatologic conditions.

Methods: A modified international 3-tier Delphi exercise was performed.

View Article and Find Full Text PDF

Drug-induced lung disease: a narrative review.

J Bras Pneumol

October 2024

. Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo - HCFMUSP - São Paulo (SP) Brasil.

Article Synopsis
  • Drug-induced lung disease (DILD) happens when certain medicines harm the lungs, affecting between 3% and 5% of people with lung diseases.
  • Symptoms can appear quickly after starting treatment and may range from not feeling sick at all to having serious breathing problems.
  • To treat DILD, doctors usually stop the harmful medication and may give steroids, but the chances of recovery can be very different for each person and some cases can be very serious.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the safety and efficacy of chemoimmunotherapy in patients with extensive-stage small-cell lung cancer (SCLC) who also had mild interstitial lung disease (ILD).
  • In a trial with 21 patients, a low incidence of pneumonitis was observed, with a severe pneumonitis-free rate of 95.2% and only two patients experiencing pneumonitis during treatment.
  • The findings suggest that chemoimmunotherapy could be a viable treatment option for these patients, with a median overall survival of 10.7 months.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!